OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
AstraZeneca
52,121 participants
Aug 21, 2023
OBSERVATIONAL
Conditions
Summary
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
Eligibility
Inclusion Criteria4
- Patients aged \>18 years at study index date AND
- A reported diagnosis code for amyloidosis OR
- A claim for ATTR-specific treatment OR
- A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR
Exclusion Criteria2
- Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
- At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
not applicable, this is an observational retrospective data analysis study; no interventions in the study
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06355934